Article
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
Cell - 6 Jun 2024
Williams Wilton B, Alam S Munir, Ofek Gilad, Erdmann Nathaniel, Montefiori David C, Seaman Michael S, Wagh Kshitij, Korber Bette, Edwards Robert J, Mansouri Katayoun, Eaton Amanda, Cain Derek W, Martin Mitchell, Hwang JongIn, Arus-Altuz Aria, Lu Xiaozhi, Cai Fangping, Jamieson Nolan, Parks Robert, Barr Maggie, Foulger Andrew, Anasti Kara, Patel Parth, Sammour Salam, Parsons Ruth J, Huang Xiao, Lindenberger Jared, Fetics Susan, Janowska Katarzyna, Niyongabo Aurelie, Janus Benjamin M, Astavans Anagh, Fox Christopher B, Mohanty Ipsita, Evangelous Tyler, Chen Yue, Berry Madison, Kirshner Helene, Van Itallie Elizabeth, Saunders Kevin O, Wiehe Kevin, Cohen Kristen W, McElrath M Juliana, Corey Lawrence, Acharya Priyamvada, Walsh Stephen R, Baden Lindsey R, Haynes Barton F
Abstract excerpt
A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
